New White Paper Available: EU Revision of the Pharmaceutical Legislation. To request access, email thoughtleadershipgroup@iqvia.com

On 26 April 2023, the European Commission proposed their long-awaited revisions to the EU’s pharmaceutical legislation aimed at making medicines more available, accessible and affordable. We analysed five of the more contentious proposals, applying IQVIA’s unique data and insights to explore their impact on life science companies, payers and, ultimately, evaluate the extent at which the Commission’s proposals may shake up European healthcare.

The five areas are:

1. Reliance on Regulatory Data Protection (RDP). These changes, see Figure 1, need to be looked at in combination with the wider EU Pharmaceutical Strategy for a full assessment. Companies will be impacted differently, depending on their portfolio. We provide an analysis on what this means for different stakeholders.
2. Changes to orphan medicines. There may be a smaller consequence on how orphan medicines are brought to market. We go into details in the report.
3. Access across all EU member states within two (or three) years. IQVIA believes that launching within two years is not possible under the current decentralised system.
4. Transferrable anti-microbial resistance (AMR) vouchers. We discuss the voucher’s potential as an incentive and propose a hybrid purchasing framework instead.
5. Incentives for the repurposing of medicines. Finally, repurposed medicines are in the spotlight. But will these changes be enough to allow them to gain a price premium?